

Open Science – a pharmaceutical industry perspective

Carlo Incerti

Sr Vice President, Head of Global
Medical Affairs, Sanofi Genzyme



 **BIO**
International
Convention

— ♥ ♀ ♂ —
25 YEARS
OF **Bio** INNOVATION

Why do we need open science?

- Pressure on the current healthcare systems
- Open Science is critical to:
 - make progress in complex areas (e.g. Alzheimer's disease)
 - drive innovation
 - accelerate translation of science into health solutions
 - support cross-sector/multidisciplinary collaboration
 - create economic benefits

Open Science – it's easy to agree on high-level principles, but the devil is in the details!

Challenges and Opportunities

- IP – need creativity & respect for ownership
- Process – must be agile
- Impact – cooperation between different stakeholders

Towards Open Science in IMI

- High EU political commitment to move towards Open Science
"Excellence, Openness and Impact are the core values of the EU R&I Programme" Commissioner Moedas, 2017
- In IMI, the concept of open science has evolved from the precompetitive area and is now closer to the bedside.

Towards Open Science in IMI

- Ultra-DD – 5y / EUR 50M (~\$ 61.25M)

Delivering new tools and resources to speed up the development of truly innovative medicines, especially in the areas of autoimmune and inflammatory diseases, through an **open access policy** to ensure that the tools, resources, and knowledge generated will benefit the entire scientific community.

4 industry partners / 1 biotech / 5 public partners

- FAIRification project – 3y / EUR 8M (~\$ 9.8M)

Making a significant portion of the data from IMI projects **findable, accessible, interoperable and reusable** with other datasets and databases will greatly improve the use and impact of the data for translational biomedical research.

7 industry partners / 2 biotechs / 1 research infrastructure / 13 public partners



Thank you!

www.imi.europa.eu

